Newm-035 -

: The drug targets a specific protein called USAG-1 (uterine sensitization-associated gene-1). In nature, USAG-1 acts as a "biological parking brake" that prevents dormant tooth buds in the human jaw from developing into full teeth after the adult set has grown.

: Launched in September 2024 at Kyoto University Hospital. This phase involves 30 healthy adult males aged 30–64 who are missing at least one molar, primarily focusing on safety and dosage.

The code appears to be a misnomer or a very specific internal project identifier for which there is no broad public record. However, it is most frequently associated in recent medical research contexts with TRG-035 , a groundbreaking tooth regeneration drug currently undergoing human clinical trials in Japan. NEWM-035

The drug was developed by , a spinoff from Kyoto University, led by Dr. Katsu Takahashi.

: The treatment is administered via an intravenous injection . By neutralizing USAG-1, the drug reactivates these dormant buds, allowing the body to use its natural BMP and Wnt signaling pathways to form new, functional teeth. Clinical Development and Trials : The drug targets a specific protein called

Below is an overview of the development and science behind . TRG-035: The World's First Tooth Regrowth Drug

: Success in Phase I will lead to trials for children aged 2–7 with congenital anodontia (being born without a full set of teeth). Future Outlook This phase involves 30 healthy adult males aged

: Preclinical trials on mice and ferrets—chosen for their similar dental structures—successfully produced new teeth with normal enamel and root structures and no significant side effects.